Shares of Vaxart Inc. VXRT,
fell 42.9% in pre-market negotiations on Wednesday after the company said its oral candidate vaccine COVID-19 was well tolerated in a Phase 1 clinical trial, but did not generate neutralizing antibodies among participants. Vaxart said its experimental vaccine was immunogenic in preliminary results; however, he also said that neutralizing antibodies were not detected in the serum or IgG antibodies were not found in “most individuals”. IgG antibodies are often detected in people who have recovered from a COVID-19 infection. The data was shared in a press release. The company said that additional data from the Phase 1 test will be presented on Wednesday afternoon at a symposium in New York. The clinical study tested two dosing schedules in 20 participants. Vaxart’s shares soared 1,358.1% last year. The S&P 500 SPX,
increased 18.6% in the last 12 months.
